Drugs / Tilmanocept
Tilmanocept
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Lymphoseek | — | 2014-11-19 | europa.eu ↗ |
Trials 9 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04663126 | Feb 2021 → Jan 2023 | melanoma | John O. Prior | Terminated | No outcome recorded |
| Phase 14 trials | ||||||
| Phase 1 | NCT03332940 | Dec 2017 → Mar 2019 | metabolic dysfunction-associated steatohepatitis | Navidea Biopharmaceuticals | Terminated | No outcome recorded |
| Phase 1 | NCT03241446 | Sep 2017 → Jan 2018 | rheumatoid arthritis | Navidea Biopharmaceuticals | Withdrawn | No outcome recorded |
| Phase 1 | NCT03029988 | Jul 2017 → Sep 2018 | colorectal carcinoma, metastasis from malignant tumor of colon | Navidea Biopharmaceuticals | Terminated | No outcome recorded |
| Phase 1 | NCT02683421 | Jul → Dec 2016 | rheumatoid arthritis | Navidea Biopharmaceuticals | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02865434 | Jan 2017 → Jun 2018 | rheumatoid arthritis | Navidea Biopharmaceuticals | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT04078191 | Sep 2021 → Jul 2024 | rheumatoid arthritis | Navidea Biopharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT02201420 | Sep 2014 → Mar 2015 | Kaposi's sarcoma | Navidea Biopharmaceuticals | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05246280 | Mar 2022 → Jul 2024 | rheumatoid arthritis | Navidea Biopharmaceuticals | Terminated | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT04487912 Comparator | Nov 2020 → May 2021 | breast cancer | University Hospital, Ghent | Withdrawn | No outcome recorded |
| Phase 4 | NCT03199560 Comparator | Jun 2017 → Jun 2019 | breast cancer | Memorial Health University Medical Center | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tilmanocept | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02683421 ↗ |
| Known as | Tc-99m tilmanocept | “Drug: Tc-99m tilmanocept” NCT04663126 ↗ |
| Known as | Technetium Tc 99m tilmanocept | “Drug: Technetium Tc 99m tilmanocept” NCT03029988 ↗ |
| Modality | Diagnostic / imaging agent | “Tilmanocept is a radiotracer” NCT02865434 ↗ |
| Route | Subcutaneous | “Evaluation of Subcutaneous (SC) Injected Tc 99m Tilmanocept Localization” NCT02683421 ↗ |